Ross Moat sold $2.3M of KNSA
CHIEF COMMERCIAL OFFICER at Kiniksa Pharmaceuticals International, plc. 87,269 shares at an average of $25.96, traded Apr 29, 2025, filed May 1, 2025.
Score components
- +15RoleOfficer
- +25Trade size$2.3M at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-011692, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 29, 2025 | MOption exercise Class A Ordinary Share10b5-1 | +15,000 | $15.52 | $233k | 24,415 | May 1, 2025 |
| Apr 29, 2025 | MOption exercise Class A Ordinary Share10b5-1 | +20,000 | $15.50 | $310k | 44,415 | May 1, 2025 |
| Apr 29, 2025 | MOption exercise Class A Ordinary Share10b5-1 | +6,296 | $12.97 | $82k | 50,711 | May 1, 2025 |
| Apr 29, 2025 | MOption exercise Class A Ordinary Share10b5-1 | +7,432 | $11.97 | $89k | 58,143 | May 1, 2025 |
| Apr 29, 2025 | MOption exercise Class A Ordinary Share10b5-1 | +15,307 | $10.76 | $165k | 73,450 | May 1, 2025 |
| Apr 29, 2025 | SOpen-market sale Class A Ordinary Share10b5-1 | -64,035 | $25.21 | $1.6M | 9,415 | May 1, 2025 |
| May 1, 2025 | MOption exercise Class A Ordinary Share10b5-1 | +13,406 | $13.35 | $179k | 22,821 | May 1, 2025 |
| May 1, 2025 | MOption exercise Class A Ordinary Share10b5-1 | +8,671 | $11.10 | $96k | 31,492 | May 1, 2025 |
| May 1, 2025 | MOption exercise Class A Ordinary Share10b5-1 | +1,157 | $17.76 | $21k | 32,649 | May 1, 2025 |
| May 1, 2025 | SOpen-market sale Class A Ordinary Share10b5-1 | -23,234 | $28.02 | $651k | 9,415 | May 1, 2025 |
| Apr 29, 2025 | MOption exercise Share Optionderivative10b5-1 | -15,000 | $0.00 | $0 | 0 | May 1, 2025 |
| Apr 29, 2025 | MOption exercise Share Optionderivative10b5-1 | -20,000 | $0.00 | $0 | 0 | May 1, 2025 |
| Apr 29, 2025 | MOption exercise Share Optionderivative10b5-1 | -6,296 | $0.00 | $0 | 1,658 | May 1, 2025 |
| Apr 29, 2025 | MOption exercise Share Optionderivative10b5-1 | -7,432 | $0.00 | $0 | 27,252 | May 1, 2025 |
| Apr 29, 2025 | MOption exercise Share Optionderivative10b5-1 | -15,307 | $0.00 | $0 | 23,361 | May 1, 2025 |
| May 1, 2025 | MOption exercise Share Optionderivative10b5-1 | -13,406 | $0.00 | $0 | 27,594 | May 1, 2025 |
| May 1, 2025 | MOption exercise Share Optionderivative10b5-1 | -8,671 | $0.00 | $0 | 21,059 | May 1, 2025 |
| May 1, 2025 | MOption exercise Share Optionderivative10b5-1 | -1,157 | $0.00 | $0 | 37,511 | May 1, 2025 |
Related signals
Other insiders at Kiniksa Pharmaceuticals International, plc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Kiniksa Pharmaceuticals International, plc | Michael R Megna CHIEF ACCOUNTING OFFICER | $369k 4,600 shares | -14% | |
| 40Moderate | Kiniksa Pharmaceuticals International, plc | Mark Ragosa CHIEF FINANCIAL OFFICER | $1.7M 36,722 shares | -75% | |
| 23Weak | Kiniksa Pharmaceuticals International, plc | John F. Paolini CHIEF MEDICAL OFFICER | $1.8M 40,000 shares | -39% | |
| 4Weak | Kiniksa Pharmaceuticals International, plc | Barry D Quart director | $126k 2,800 shares | -22% | |
| 37Weak | Kiniksa Pharmaceuticals International, plc | Mark Ragosa CHIEF FINANCIAL OFFICER | $772k 17,845 shares | -60% | |
| 29Weak | Kiniksa Pharmaceuticals International, plc | Barry D Quart director | $722k 15,960 shares | -119% | |
| 30Weak | Kiniksa Pharmaceuticals International, plc | Mark Ragosa CHIEF FINANCIAL OFFICER | $503k 12,000 shares | -39% | |
| 38Weak | Kiniksa Pharmaceuticals International, plc | Barry D Quart director | $836k 20,129 shares | -62% | |
| 28Weak | Kiniksa Pharmaceuticals International, plc | Eben Tessari CHIEF OPERATING OFFICER | $501k 12,048 shares | -42% | |
| 47Moderate | Kiniksa Pharmaceuticals International, plc | Mark Ragosa CHIEF FINANCIAL OFFICER | $1.8M 42,841 shares | -58% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.